Cronos Group Q2 Earnings: Record Revenue, Expanding Margins and a Balance Sheet Built for Optionality

On Thursday, Cronos Group (NASDAQ: CRON) (TSX: CRON) reported second-quarter net revenue of $53.0 million, gross profit of $28.5 million, adjusted EBITDA of $13.1 million and net income of $35.7 million.

A closer look at the results, however, suggests the quarter was driven by more than just higher sales. International demand, a more favorable product mix and expanding gross margins all contributed to stronger operating performance, although part of the increase in net income also reflected foreign currency gains rather than operations alone.

Three Numbers That Defined the Quarter

Three metrics explain most of Cronos’ second-quarter performance.

Net revenue increased 58% year over year to $53.0 million, or 51% on an organic constant-currency basis, driven primarily by higher flower sales in Israel, growing demand in Germany, and stronger Canadian flower and extract sales.

Gross profit nearly doubled to $28.5 million, while gross margin expanded from 43% to 54%.

Management attributed the improvement to a more favorable geographic sales mix, particularly higher sales into Israel and other international markets that are not subject to Canadian excise taxes, as well as greater production efficiencies from higher volumes.

Adjusted EBITDA increased from $1.7 million a year ago to $13.1 million, reflecting stronger operating performance despite higher operating expenses.

International Markets Are Becoming a Bigger Driver

The quarter reinforces a trend that has been developing for several quarters: Cronos is becoming increasingly dependent on international growth.

Revenue in Israel increased 60% year over year, marking the company’s tenth consecutive quarter of record net revenue in that market.

Revenue from countries outside Canada and Israel rose 88%, led primarily by demand for PEACE NATURALS products in Germany.

Canada also posted record quarterly revenue, supported by continued market share gains for the Spinach brand in vapes and edibles.

That geographic diversification matters because it reduces reliance on any single cannabis market while exposing the company to faster-growing medical markets abroad.

Higher Margins Offset Rising Operating Costs

Revenue growth alone rarely tells investors whether a business is becoming more efficient.

Cronos increased gross profit by 96%, substantially outpacing revenue growth. At the same time, total operating expenses increased to $21.0 million from $19.8 million a year earlier as the company invested more in sales and marketing, research and development, and general administrative functions.

The relationship between those figures is important. Gross profit expanded much faster than operating expenses, allowing operating income to improve from a $5.3 million operating loss a year ago to $7.4 million in operating income this quarter.

Net Income Deserves Additional Context

Cronos reported $35.7 million in net income, compared with a $38.5 million net loss in the prior-year quarter.

While stronger gross profit clearly contributed to that improvement, management also attributed part of the increase to foreign currency transaction gains recorded during the quarter. Those gains are reflected in “other income” and are not directly related to cannabis operations. At the same time, operating expenses increased as the company continued investing in commercial activities and research.

The quarter demonstrated genuine operational improvement, but reported net income also benefited from factors that may not recur every quarter.

Capital Allocation Continues to Stand Out

One of Cronos’ strongest competitive advantages remains its balance sheet.

Cronos also continued returning capital to shareholders. During the first half of 2026, the company repurchased 12.3 million shares, reducing its outstanding share count by roughly 3% while ending the quarter with $827 million in cash, cash equivalents and interest-bearing deposits.

Cronos is using its balance sheet to reduce dilution while retaining significant financial flexibility for acquisitions and other strategic investments.

Cronos also remained disciplined with capital spending.

Capital expenditures declined to $1.8 million in the second quarter from $3.8 million a year earlier, and were down 80% year to date.

A Regulatory Risk Investors Should Watch

Although Israel remains one of Cronos’ fastest-growing markets, the company disclosed that Israeli authorities have initiated a new anti-dumping investigation into Canadian medical cannabis imports following the filing of a new complaint by domestic producers. Cronos disputes the allegations and said it cannot predict the outcome or whether import restrictions or duties could eventually be imposed.

Given Israel’s importance to revenue growth, developments in that investigation could become increasingly relevant over coming quarters.

The Quarter Leaves Several Questions

Investors may now be looking for greater clarity on several issues. International markets are driving an increasing share of revenue growth, raising questions about how sustainable current demand trends in Israel and Germany will be.

While margins expanded significantly this quarter, operating expenses also continued to rise, making it important to determine whether future revenue growth can continue to outpace cost growth.

Finally, with more than $827 million in cash and interest-bearing deposits, investors will likely want additional insight into how aggressively management intends to balance acquisitions, share repurchases and organic investment.